Accelerating Peptide Development: Strategies to optimize the formulation and manufacture of peptide therapeutics

Register here


How do I select the most appropriate first-in-human formulation? Quotient is your answer.
FIH - Formulation Development scientists working together

Quotient Sciences’ focus is on delivering the most appropriate formulations to expedite your clinical program, through dosing within our own Phase I clinical facilities or at an external site. We work with you to support rapid progression to your first-in-human evaluation where required, ensuring that your ultimate drug product presentation goals can be seamlessly transitioned following confirmation of molecule safety and tolerability. Our formulators’ experience is built on years of work integrating formulation development and clinical evaluation. As a result, our development is based on an understanding of the intended indication including drug products designed for chronic dosing or for pediatric populations.

FIH - Formulation Development

Our breadth of formulations developed for first-in-human studies includes:

  • APIs in a bottle or capsule
  • Solutions
  • Suspensions
  • Tablets
  • Capsules
  • Parenterals
  • Solubility-enhanced dosage forms
Get in touch to find out how Quotient Sciences can put speed, precision and quality at the heart of your pipeline
Connect With Quotient
We use cookies to help us to improve our site and enables us to the best possible service and customer experience. By clicking accept you are agreeing to let us share your data with select third parties for analytics and marketing purposes.